First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...
Ulster University

Cú Chulainn and Il'ya of Murom: Two Heroes, and Some Variations on a Theme

Cú Chulainn and Il’ya of Murom can be identified as emblematic heroes of the old (or early medieval) Irish and the medieval Slavo-Russian narrative contexts. They are drawn together most particularly ...